79 related articles for article (PubMed ID: 28187031)
1. X-Ray of Excised Cancerous Breast Tissue Does Not Affect Clinical Biomarker Expression.
Lloyd IE; Welm AL; DeRose Y; Neumayer LA; Kohan JL; Malmberg EM; Salama ME; Factor RE
Appl Immunohistochem Mol Morphol; 2018 Aug; 26(7):501-508. PubMed ID: 28187031
[TBL] [Abstract][Full Text] [Related]
2. The effect of delay in fixation, different fixatives, and duration of fixation in estrogen and progesterone receptor results in breast carcinoma.
Apple S; Pucci R; Lowe AC; Shintaku I; Shapourifar-Tehrani S; Moatamed N
Am J Clin Pathol; 2011 Apr; 135(4):592-8. PubMed ID: 21411782
[TBL] [Abstract][Full Text] [Related]
3. Effect of fixation time on breast biomarker expression: a controlled study using cell line-derived xenografted (CDX) tumours.
Kao KR; Hasan T; Baptista A; Truong T; Gai L; Smith AC; Li S; Gonzales P; Voisey K; Eriwvo P; Power J; Denic N
J Clin Pathol; 2017 Oct; 70(10):832-837. PubMed ID: 28341657
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
Allott EH; Geradts J; Sun X; Cohen SM; Zirpoli GR; Khoury T; Bshara W; Chen M; Sherman ME; Palmer JR; Ambrosone CB; Olshan AF; Troester MA
Breast Cancer Res; 2016 Jun; 18(1):68. PubMed ID: 27349894
[TBL] [Abstract][Full Text] [Related]
5. Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer.
Roepman P; Horlings HM; Krijgsman O; Kok M; Bueno-de-Mesquita JM; Bender R; Linn SC; Glas AM; van de Vijver MJ
Clin Cancer Res; 2009 Nov; 15(22):7003-11. PubMed ID: 19887485
[TBL] [Abstract][Full Text] [Related]
6. Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer.
Moatamed NA; Nanjangud G; Pucci R; Lowe A; Shintaku IP; Shapourifar-Tehrani S; Rao N; Lu DY; Apple SK
Am J Clin Pathol; 2011 Nov; 136(5):754-61. PubMed ID: 22031314
[TBL] [Abstract][Full Text] [Related]
7. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype.
Deyarmin B; Kane JL; Valente AL; van Laar R; Gallagher C; Shriver CD; Ellsworth RE
Ann Surg Oncol; 2013 Jan; 20(1):87-93. PubMed ID: 22875649
[TBL] [Abstract][Full Text] [Related]
8. The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma.
Yildiz-Aktas IZ; Dabbs DJ; Cooper KL; Chivukula M; McManus K; Bhargava R
Am J Clin Pathol; 2012 May; 137(5):691-8. PubMed ID: 22523206
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.
Wernicke AG; Varma S; Greenwood EA; Christos PJ; Chao KS; Liu H; Bander NH; Shin SJ
APMIS; 2014 Jun; 122(6):482-9. PubMed ID: 24304465
[TBL] [Abstract][Full Text] [Related]
10. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
[TBL] [Abstract][Full Text] [Related]
11. Fresh Cut Versus Stored Cut Paraffin-embedded Tissue: Effect on Immunohistochemical Staining for Common Breast Cancer Markers.
Forse CL; Pinnaduwage D; Bull SB; Mulligan AM; Andrulis IL
Appl Immunohistochem Mol Morphol; 2019 Mar; 27(3):231-237. PubMed ID: 29553968
[TBL] [Abstract][Full Text] [Related]
12. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.
Osborne JR; Port E; Gonen M; Doane A; Yeung H; Gerald W; Cook JB; Larson S
J Nucl Med; 2010 Apr; 51(4):543-50. PubMed ID: 20237034
[TBL] [Abstract][Full Text] [Related]
15. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
Guo L; Yuan P; Zhang J; Ling Y; Li W; Zhao B; Ying J; Xuan L
Breast Cancer Res Treat; 2017 Nov; 166(1):77-84. PubMed ID: 28712009
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples.
Kinsella MD; Birdsong GG; Siddiqui MT; Cohen C; Hanley KZ
Diagn Cytopathol; 2013 Mar; 41(3):192-8. PubMed ID: 22611048
[TBL] [Abstract][Full Text] [Related]
18. Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.
Chapman JA; Sgroi DC; Goss PE; Zarella E; Binns S; Zhang Y; Schnabel CA; Erlander MG; Pritchard KI; Han L; Badovinac-Crnjevic T; Shepherd LE; Pollak MN
Breast Cancer Res Treat; 2016 May; 157(1):101-8. PubMed ID: 27116182
[TBL] [Abstract][Full Text] [Related]
19. An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines.
O'Grady A; Allen D; Happerfield L; Johnson N; Provenzano E; Pinder SE; Tee L; Gu M; Kay EW
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):489-93. PubMed ID: 20661132
[TBL] [Abstract][Full Text] [Related]
20. Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.
Calhoun BC; Collins LC
Semin Diagn Pathol; 2015 Sep; 32(5):362-9. PubMed ID: 25770732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]